1. Hyjek E, Isaacsjn P. Hum Pathol 1988; 19: 1315–26.
2. Isaacson P. Ann Oncol 1995; 319–20.
3. Armitage JO, Weisenburger DDJ. Clin Oncol J 1998; 16: 2780–95.
4. Thieblemont C, Berger F, Dumontet C et al. Blood 2000; 95: 802–6.
5. Wotherspoon AC, Doglioni C, Isaacson PG. Histopathology 1992; 20: 29.
6. Bernard SM, Cartwright RA, Bird CC et al. Leuk Res 1984; 8: 681.
7. Gospodarowicz M, Bush R, Brown T et al. Int J Radiat Oncol Biol Phys 1983; 9: 3–9.
8. Gospodarowicz M, Sutcliffe SB, Clark RM et al. Int J Radiat Oncol Biol Phys 1990; 19: 1351–5.
9. Gospodarowicz M, Pintille M, Tsang R et al. Recent Result Cancer Res 2000; 156: 108–15.
10. Thirlby RC. Oncology 1993; 7: 29–32.
11. Sano T. Recent Results Cancer Res 2000; 156: 104–7.
12. Maor MH, Velasquez WS, Fuller LM et al. J Clin Oncolog 1990; 8: 266.
13. Montalban C, Santon A, Redondo C et al. An Oncology 2005; 16 (9): 1539–45.
14. Zucca E, Conconi A, Gospodarowicz M, Cavalli F et al. Blood 2002; 94: 4214–21.
15. Conconi A, Martinelli G, Thieblemont C, Ferreri AJ et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003 Oct 15; 102 (8): 2741–5. Epub 2003 Jul 3.
16. Khojasteh A, Haghshenass M. N Engl J Med 1983; 308: 1401.
17. Price SK. Histopathology 1990; 17: 7–17.
18. Ben Ayed F, Halphen M, Najjar T et al. Cancer 1989; 63: 1251–6.
19. Isaacson PG, Matutes E, Burke M et al. Am J Surg Pathol 1989; 13: 1023–33.
20. Isaacson PG, Hum Pathol 1994; 25: 1020–9.
21. Salem PA, Nassas VH, Shahid MJ et al. Cancer 1977; 40: 2941.
22. Peng H. An Oncol 1999; 10 (suppl. 3): abs. 018.